NASDAQ:HELP Cybin (HELP) Stock Price, News & Analysis $5.31 -0.03 (-0.56%) Closing price 05/8/2026 04:00 PM EasternExtended Trading$5.32 +0.01 (+0.19%) As of 05/8/2026 07:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Cybin Stock (NASDAQ:HELP) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Cybin alerts:Sign Up Key Stats Today's Range$5.16▼$5.4450-Day Range$4.32▼$8.5352-Week Range$4.29▼$9.83Volume617,427 shsAverage Volume1.69 million shsMarket Capitalization$274.16 millionP/E RatioN/ADividend YieldN/APrice Target$58.75Consensus RatingBuy Company Overview Cybin Inc. is a clinical-stage biopharmaceutical company focused on the development of psychedelic-based therapeutics for the treatment of mental health disorders. Headquartered in Toronto and listed on the NASDAQ under the symbol HELP, Cybin pursues research and development programs intended to harness the therapeutic potential of psychedelic compounds to address conditions with significant unmet need. The company operates a drug discovery and development platform aimed at creating novel small-molecule psychedelic analogs and tailored formulations. Cybin’s work spans preclinical research through clinical trials, with an emphasis on optimizing pharmacology, dosing and delivery to improve safety, tolerability and the patient experience. Its R&D approach combines chemistry, formulation science and clinical development to advance candidate therapies toward regulatory review. Cybin’s therapeutic efforts target a range of mental health indications that commonly include mood and anxiety disorders and substance-use disorders. The company pursues both internal development programs and collaborative relationships with academic and industry partners to support clinical development, regulatory strategy and potential commercialization pathways. As a publicly traded biotechnology company, Cybin’s operations encompass research and development activities across multiple jurisdictions, with clinical programs conducted in regions where regulatory frameworks permit investigational studies of psychedelic-assisted treatments. The company positions itself to expand therapeutic options for patients and to contribute to the evolving scientific and clinical understanding of psychedelic-derived medicines. AI Generated. May Contain Errors. Read More Cybin Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks69th Percentile Overall ScoreHELP MarketRank™: Cybin scored higher than 69% of companies evaluated by MarketBeat, and ranked 21st out of 56 stocks in the manufacturing sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.0 / 5Analyst RatingBuy Consensus RatingCybin has received a consensus rating of Buy. The company's average rating score is 3.17, and is based on 1 strong buy rating, 5 buy ratings, no hold ratings, and no sell ratings.Upside PotentialCybin has a consensus price target of $58.75, representing about 1,006.4% upside from its current price of $5.31.Amount of Analyst CoverageCybin has only been the subject of 2 research reports in the past 90 days.Read more about Cybin's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Cybin are expected to grow in the coming year, from ($4.08) to ($3.38) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Cybin is -1.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cybin is -1.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCybin has a P/B Ratio of 0.67. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for HELP. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCybin does not currently pay a dividend.Dividend GrowthCybin does not have a long track record of dividend growth. News and Social Media4.0 / 5News Sentiment1.35 News SentimentCybin has a news sentiment score of 1.35. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.53 average news sentiment score of Manufacturing companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Cybin this week, compared to 3 articles on an average week.Search Interest47 people have searched for HELP on MarketBeat in the last 30 days. This is an increase of 57% compared to the previous 30 days.MarketBeat Follows16 people have added Cybin to their MarketBeat watchlist in the last 30 days. This is an increase of 167% compared to the previous 30 days. Company Ownership0.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Cybin insiders have not sold or bought any company stock.Percentage Held by Insiders15.00% of the stock of Cybin is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions17.94% of the stock of Cybin is held by institutions.Read more about Cybin's insider trading history. Receive HELP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cybin and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. HELP Stock News HeadlinesCORRECTION: Helus Pharma Partners with TARA Mind to Advance Veteran Mental HealthApril 30, 2026 | globenewswire.comHelus Pharma to Participate at the 29th Annual Milken Institute Global ConferenceApril 30, 2026 | globenewswire.comALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings research points to the first half of 2026 as a particularly rough stretch for certain holdings. Some of America's most popular stocks could take serious damage as a radical market shift plays out. Analysts at Weiss Ratings have identified five names you may want to remove from your portfolio before this unfolds. If any of these are in your portfolio, now is the time to review your positions.May 9 at 1:00 AM | Weiss Ratings (Ad)Helus Pharma Partners with TARA Mind to Advance Veteran Mental HealthApril 28, 2026 | globenewswire.comDoes Robert Langer’s Arrival Reframe Confidence in Cybin’s (HELP) Clinical Strategy and Execution Risk?April 25, 2026 | finance.yahoo.comHelus Pharma Strengthens Scientific Advisory Board with Addition of Dr. Robert Langer and Dr. Stephen BrannanApril 23, 2026 | globenewswire.comCybin: Regulatory Tailwinds Unlock Asymmetric Upside (Rating Upgrade)April 22, 2026 | seekingalpha.comPsychedelic drug stocks soar as Trump fast‑tracks FDA reviewsApril 20, 2026 | usatoday.comSee More Headlines HELP Stock Analysis - Frequently Asked Questions How have HELP shares performed this year? Cybin's stock was trading at $7.25 at the beginning of 2026. Since then, HELP stock has decreased by 26.8% and is now trading at $5.31. How were Cybin's earnings last quarter? Cybin Inc. (NASDAQ:HELP) released its quarterly earnings results on Friday, February, 13th. The company reported ($0.72) EPS for the quarter, missing the consensus estimate of ($0.53) by $0.19. How do I buy shares of Cybin? Shares of HELP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings2/13/2026Today5/09/2026Fiscal Year End3/31/2027Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (2m+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 HELP's financial health is in the Yellow zone, according to TradeSmith. HELP has been in this zone for over 2 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorManufacturing Industry N/A Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:HELP Previous SymbolCBOE:HELP CIK1833141 WebN/A Phone(908) 764-8385FaxN/AEmployees50Year Founded2019Price Target and Rating Average Price Target for Cybin$58.75 High Price Target$95.00 Low Price Target$22.00 Potential Upside/Downside+1,006.4%Consensus RatingBuy Rating Score (0-4)3.17 Research Coverage6 Analysts Profitability EPS (Trailing Twelve Months)($4.23) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$81.31 million Net MarginsN/A Pretax MarginN/A Return on Equity-59.98% Return on Assets-50.80% Debt Debt-to-Equity RatioN/A Current Ratio13.78 Quick Ratio13.78 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$7.89 per share Price / Book0.67Miscellaneous Outstanding Shares51,630,000Free Float43,887,000Market Cap$274.16 million OptionableN/A Beta0.80 Social Links 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Click the link to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free Report This page (NASDAQ:HELP) was last updated on 5/9/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | SponsoredIran's New Leader Just Said Something That Should Terrify Every AmericanIran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...American Alternative | SponsoredYour book attachedYour Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...Profits Run | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredSell 99% of Your Stocks, Do THIS Instead…Millionaire Trader Exposes: "The Single Stock Income Plan" With over 6,000 stocks on the market to choose ...The Oxford Club | SponsoredTrade this between 9:30 and 10:45 am ESTThe first 75 minutes of the trading day may be the most overlooked window for consistent opportunities.If you ...Base Camp Trading | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | SponsoredElon Unveils AI Passive Income Stream for Millions of AmericansDuring Tesla's last earnings call, Elon Musk outlined a new AI-driven approach he says could generate $30,000-...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cybin Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cybin With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free HELP Stock Alerts